View ValuationCenter Laboratories 将来の成長Future 基準チェック /06現在、 Center Laboratoriesの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長16.5%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesReported Earnings • Aug 15Second quarter 2026 earnings released: NT$13.78 loss per share (vs NT$0.96 loss in 2Q 2025)Second quarter 2026 results: NT$13.78 loss per share (further deteriorated from NT$0.96 loss in 2Q 2025). Revenue: NT$432.1m (up 14% from 2Q 2025). Net loss: NT$10.4b (loss widened NT$9.72b from 2Q 2025). Over the last 3 years on average, earnings per share has increased by 113% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.Upcoming Dividend • Aug 10Upcoming dividend of NT$1.75 per shareEligible shareholders must have bought the stock before 17 August 2026. Payment date: 11 September 2026. Payout ratio is a comfortable 12% but the company is not cash flow positive. Trailing yield: 4.4%. Lower than top quartile of Taiwanese dividend payers (5.1%). Higher than average of industry peers (3.1%).Reported Earnings • May 15First quarter 2026 earnings released: EPS: NT$2.00 (vs NT$0.72 in 1Q 2025)First quarter 2026 results: EPS: NT$2.00 (up from NT$0.72 in 1Q 2025). Revenue: NT$466.0m (up 23% from 1Q 2025). Net income: NT$1.97b (up 258% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 121% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.お知らせ • Apr 01WuXi XDC Cayman Inc. (SEHK:2268) completed the acquisition of 60% stake in BioDlink International Company Limited (SEHK:1875) from a group of shareholders.WuXi XDC Cayman Inc. (SEHK:2268) proposed to acquire 60% stake in BioDlink International Company Limited (SEHK:1875) from a group of shareholders for HKD 1.9 billion on January 14, 2026. A cash consideration valued at HKD 4 per share will be paid by WuXi XDC Cayman Inc. The Board of Directors of BioDlink International Company Limited formed a special committee for the transaction. The transaction is subject to minimum tender. The transaction is expected to close on March 27, 2026. As of March 13, 2026 The Offeror received valid acceptances for 46.54% of the company's issued share capital by the first closing date. However, the acceptance condition of holding at least 60% of voting rights was not met, leading to an extension of the offer to March 27, 2026. As of March 17, 2026, the Offeror had received valid acceptances for the Share Offer in respect of 463,672,734 Offer Shares, representing approximately 60% of the total issued share capital of BioDlink International Company Limited. the Offeror had received valid acceptances for the Option Offer in respect of 6,512,600 Share Options representing approximately 85.33% of the total outstanding Share Options. The transaction is expected to close on March 31, 2026. Citigroup Global Markets Asia Limited acted as financial advisor for WuXi XDC Cayman Inc. Grand Moore Capital Limited act as financial advisor for special committee. Tricor Investor Services Limited acted as Registrar to BioDlink International Company Limited. Grand Moore Capital Limited acted as financial advisor to independent board committee of BioDlink International Company Limited. WuXi XDC Cayman Inc. (SEHK:2268) completed the acquisition of 60% stake in BioDlink International Company Limited (SEHK:1875) from a group of shareholders on March 31, 2026.New Risk • Mar 04New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 37% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 24% per year over the past 5 years. High level of non-cash earnings (37% accrual ratio).Reported Earnings • Mar 04Full year 2025 earnings released: EPS: NT$12.33 (vs NT$1.48 loss in FY 2024)Full year 2025 results: EPS: NT$12.33 (up from NT$1.48 loss in FY 2024). Revenue: NT$1.52b (down 6.3% from FY 2024). Net income: NT$9.32b (up NT$10.4b from FY 2024). Over the last 3 years on average, earnings per share has increased by 97% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.お知らせ • Mar 04Center Laboratories, Inc., Annual General Meeting, Jun 12, 2026Center Laboratories, Inc., Annual General Meeting, Jun 12, 2026. Location: 4 floor building. e no,19-11, san ch`ung rd., nangang district, taipei city TaiwanReported Earnings • Nov 12Third quarter 2025 earnings released: EPS: NT$3.80 (vs NT$0.36 in 3Q 2024)Third quarter 2025 results: EPS: NT$3.80 (up from NT$0.36 in 3Q 2024). Revenue: NT$359.1m (down 8.5% from 3Q 2024). Net income: NT$2.72b (up NT$2.44b from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.Upcoming Dividend • Sep 26Upcoming dividend of NT$0.76 per shareEligible shareholders must have bought the stock before 03 October 2025. Payment date: 10 November 2025. The company is not currently making a profit and there are not enough cash flows to support it either. Trailing yield: 1.9%. Lower than top quartile of Taiwanese dividend payers (5.3%). Lower than average of industry peers (2.5%).Reported Earnings • Aug 17Second quarter 2025 earnings released: NT$1.01 loss per share (vs NT$0.10 loss in 2Q 2024)Second quarter 2025 results: NT$1.01 loss per share (further deteriorated from NT$0.10 loss in 2Q 2024). Revenue: NT$378.7m (down 8.4% from 2Q 2024). Net loss: NT$726.5m (loss widened NT$654.1m from 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.Reported Earnings • May 14First quarter 2025 earnings released: EPS: NT$0.76 (vs NT$0.78 loss in 1Q 2024)First quarter 2025 results: EPS: NT$0.76 (up from NT$0.78 loss in 1Q 2024). Revenue: NT$378.9m (up 4.3% from 1Q 2024). Net income: NT$549.1m (up NT$1.09b from 1Q 2024). Over the last 3 years on average, earnings per share has fallen by 48% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.お知らせ • May 03Center Laboratories, Inc. to Report Q1, 2025 Results on May 12, 2025Center Laboratories, Inc. announced that they will report Q1, 2025 results on May 12, 2025Reported Earnings • Mar 19Full year 2024 earnings released: NT$1.55 loss per share (vs NT$1.50 loss in FY 2023)Full year 2024 results: NT$1.55 loss per share (further deteriorated from NT$1.50 loss in FY 2023). Revenue: NT$1.62b (up 16% from FY 2023). Net loss: NT$1.10b (loss widened 11% from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 78 percentage points per year, which is a significant difference in performance.お知らせ • Mar 12+ 1 more updateCenter Laboratories, Inc., Annual General Meeting, Jun 26, 2025Center Laboratories, Inc., Annual General Meeting, Jun 26, 2025. Location: 4 floor building. e no,19-11, san ch`ung rd., nangang district, taipei city Taiwanお知らせ • Mar 04Center Laboratories, Inc. to Report Fiscal Year 2024 Results on Mar 11, 2025Center Laboratories, Inc. announced that they will report fiscal year 2024 results on Mar 11, 2025Reported Earnings • Nov 19Third quarter 2024 earnings released: EPS: NT$0.38 (vs NT$1.49 loss in 3Q 2023)Third quarter 2024 results: EPS: NT$0.38 (up from NT$1.49 loss in 3Q 2023). Revenue: NT$392.5m (up 15% from 3Q 2023). Net income: NT$273.3m (up NT$1.25b from 3Q 2023). Profit margin: 70% (up from net loss in 3Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 112 percentage points per year, which is a significant difference in performance.お知らせ • Nov 05Center Laboratories, Inc. to Report Q3, 2024 Results on Nov 12, 2024Center Laboratories, Inc. announced that they will report Q3, 2024 results on Nov 12, 2024Reported Earnings • Aug 15Second quarter 2024 earnings released: NT$0.10 loss per share (vs NT$1.43 loss in 2Q 2023)Second quarter 2024 results: NT$0.10 loss per share (improved from NT$1.43 loss in 2Q 2023). Revenue: NT$413.4m (up 32% from 2Q 2023). Net loss: NT$72.5m (loss narrowed 92% from 2Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 127 percentage points per year, which is a significant difference in performance.お知らせ • Aug 06Center Laboratories, Inc. to Report Q2, 2024 Results on Aug 13, 2024Center Laboratories, Inc. announced that they will report Q2, 2024 results on Aug 13, 2024Upcoming Dividend • Jul 26Upcoming dividend of NT$1.43 per shareEligible shareholders must have bought the stock before 02 August 2024. Payment date: 30 August 2024. The company is not currently making a profit and is not cash flow positive. Trailing yield: 2.8%. Lower than top quartile of Taiwanese dividend payers (4.3%). Higher than average of industry peers (2.0%).Reported Earnings • May 20First quarter 2024 earnings released: NT$0.78 loss per share (vs NT$1.52 profit in 1Q 2023)First quarter 2024 results: NT$0.78 loss per share (down from NT$1.52 profit in 1Q 2023). Revenue: NT$363.4m (up 8.5% from 1Q 2023). Net loss: NT$541.0m (down 155% from profit in 1Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 126 percentage points per year, which is a significant difference in performance.お知らせ • May 16Center Laboratories, Inc. Announces the Resignation of Lin Shirley Yi-Hsien as Independent DirectorCenter Laboratories, Inc. received the resignation letter from the independent director LIN SHIRLEY YI-HSIEN on May 15,2024, effective immediately. Reason for the change is personal reason.お知らせ • May 05Center Laboratories, Inc. to Report Q1, 2024 Results on May 13, 2024Center Laboratories, Inc. announced that they will report Q1, 2024 results at 9:00 AM, Taipei Standard Time on May 13, 2024お知らせ • Mar 29Center Laboratories, Inc., Annual General Meeting, Jun 25, 2024Center Laboratories, Inc., Annual General Meeting, Jun 25, 2024.Reported Earnings • Mar 21Full year 2023 earnings released: NT$1.50 loss per share (vs NT$0.16 profit in FY 2022)Full year 2023 results: NT$1.50 loss per share (down from NT$0.16 profit in FY 2022). Revenue: NT$1.39b (up 82% from FY 2022). Net loss: NT$995.4m (down NT$1.10b from profit in FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 111 percentage points per year, which is a significant difference in performance.New Risk • Nov 18New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 5.8% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Earnings have declined by 41% per year over the past 5 years. Minor Risk Shareholders have been diluted in the past year (5.8% increase in shares outstanding).Reported Earnings • Nov 14Third quarter 2023 earnings released: NT$1.49 loss per share (vs NT$1.68 loss in 3Q 2022)Third quarter 2023 results: NT$1.49 loss per share (improved from NT$1.68 loss in 3Q 2022). Revenue: NT$341.2m (up 98% from 3Q 2022). Net loss: NT$978.7m (loss narrowed 11% from 3Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 94 percentage points per year, which is a significant difference in performance.Upcoming Dividend • Sep 01Upcoming dividend of NT$0.99 per share at 1.9% yieldEligible shareholders must have bought the stock before 08 September 2023. Payment date: 13 October 2023. The company is not currently making a profit and is not cash flow positive. Trailing yield: 1.9%. Lower than top quartile of Taiwanese dividend payers (5.6%). Higher than average of industry peers (1.5%).Reported Earnings • Aug 12Second quarter 2023 earnings released: NT$1.57 loss per share (vs NT$0.31 loss in 2Q 2022)Second quarter 2023 results: NT$1.57 loss per share (further deteriorated from NT$0.31 loss in 2Q 2022). Revenue: NT$312.3m (up 53% from 2Q 2022). Net loss: NT$933.0m (loss widened 419% from 2Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 79 percentage points per year, which is a significant difference in performance.お知らせ • Aug 12Center Laboratories, Inc. Announces Cash Dividend Distribution for the Year 2022, Payable on October 13, 2023The Board of Directors of Center Laboratories, Inc. announced dividend distribution for the year 2022. Appropriations of earnings in cash dividends to shareholders (TWD per share): TWD 1.0. Total amount of cash dividends to shareholders (TWD): 594,755,996. Ex-rights (Ex-dividend) date: September 08, 2023. Ex-rights (Ex-dividend) record date: September 16, 2023. Last date before book closure: September 11, 2023. Payment date of cash dividend distribution: October 13, 2023.Reported Earnings • Apr 01Full year 2022 earnings released: EPS: NT$0.17 (vs NT$3.14 in FY 2021)Full year 2022 results: EPS: NT$0.17 (down from NT$3.14 in FY 2021). Revenue: NT$767.7m (up 54% from FY 2021). Net income: NT$102.2m (down 94% from FY 2021). Profit margin: 13% (down from 363% in FY 2021). Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has increased by 15% per year, which means it is well ahead of earnings.お知らせ • Dec 09Center Laboratories, Inc. Announces Executive AppointmentsCenter Laboratories, Inc. announced that Mao, An-Ni - Manager of the Finance and Accounting Department of Center Laboratories, Inc., as financial and accounting officer; and Tang, Ching-Yuh /Manager of the Post-Investment Management Department of Center Laboratories, Inc. as corporate governance officer and acting spokesperson, effective December 8, 2022.since Mrs. Wang, Su-Chi was elected as the company's new Chairperson by the extraordinary board of directors' meeting on November 30, 2022; she resigned from the positions of the company's financial and accounting officer, corporate governance officer, and acting spokesperson, effective November 30, 2022.お知らせ • Dec 03Center Laboratories, Inc. Announces Management ChangesCenter Laboratories, Inc. announced since Mrs. Wang, Su-Chi was elected as the company's new Chairperson by the extraordinary board of directors' meeting on November 30, 2022; she resigned from the positions of the company's financial and accounting officer, corporate governance officer, and acting spokesperson, effective November 30, 2022.Board Change • Nov 16Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 6 new directors. No experienced directors. 1 highly experienced director. 2 independent directors (5 non-independent directors). Chairman of the Board Rong-Jin Lin is the most experienced director on the board, commencing their role in 2013. Independent Director Shirley Lin was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Upcoming Dividend • Sep 01Upcoming dividend of NT$2.43 per shareEligible shareholders must have bought the stock before 08 September 2022. Payment date: 14 October 2022. The company is not currently making a profit and is not cash flow positive. Trailing yield: 3.9%. Lower than top quartile of Taiwanese dividend payers (6.4%). Higher than average of industry peers (2.4%).Reported Earnings • Aug 14Second quarter 2022 earnings released: NT$0.36 loss per share (vs NT$2.42 profit in 2Q 2021)Second quarter 2022 results: NT$0.36 loss per share (down from NT$2.42 profit in 2Q 2021). Revenue: NT$204.6m (up 54% from 2Q 2021). Net loss: NT$179.9m (down 115% from profit in 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings.お知らせ • Aug 12Center Laboratories, Inc. Announces Cash Dividend Distribution for the Year 2021The Board of Directors of Center Laboratories, Inc. announced dividend distribution for the year 2021. Appropriations of earnings in cash dividends to shareholders (TWD per share): TWD 2.5. Total amount of cash dividends to shareholders (TWD): 1,262,621,868. Ex-rights (Ex-dividend) date: September 08, 2022. Ex-rights (Ex-dividend) record date: September 17, 2022. Last date before book closure: September 12, 2022. Payment date of cash dividend distribution: October 14, 2022.お知らせ • May 21Center Laboratories, Inc. Elects DirectorsCenter Laboratories, Inc. elected Lin, Jung Chin, Tsai, Chang-Hai and LIN SHIRLEY YI-HSIEN as directors, at its 2022 Annual Shareholders' Meeting held on May 20, 2022.Reported Earnings • May 14First quarter 2022 earnings released: EPS: NT$2.69 (vs NT$4.21 in 1Q 2021)First quarter 2022 results: EPS: NT$2.69 (down from NT$4.21 in 1Q 2021). Revenue: NT$152.0m (down 4.0% from 1Q 2021). Net income: NT$1.36b (down 36% from 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings.Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 7 non-independent directors. Independent Director Mei-Yueh Ho was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Mar 31Full year 2021 earnings released: EPS: NT$3.60 (vs NT$7.73 in FY 2020)Full year 2021 results: EPS: NT$3.60 (down from NT$7.73 in FY 2020). Revenue: NT$500.1m (down 30% from FY 2020). Net income: NT$1.82b (down 52% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.お知らせ • Mar 04Center Laboratories, Inc., Annual General Meeting, May 20, 2022Center Laboratories, Inc., Annual General Meeting, May 20, 2022. Location: Building E, Room 447, 4F, No. 19-11, Sanchong Road, Nangang District,Taipei City, Taiwan (Nankang Software Incubator) Taipei City Taiwan Agenda: To discuss 2021 business report; to discuss audit committee review report ; to consider Amendment to the ” Articles of Incorporation; to release non-competition restrictions on newly elected directors of the company and other subject matters.Reported Earnings • Nov 12Third quarter 2021 earnings released: NT$1.61 loss per share (vs NT$1.90 profit in 3Q 2020)The company reported a poor third quarter result with weaker earnings, revenues and control over costs. Third quarter 2021 results: Revenue: NT$87.9m (down 33% from 3Q 2020). Net loss: NT$813.4m (down 186% from profit in 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.Upcoming Dividend • Sep 06Upcoming dividend of NT$1.50 per shareEligible shareholders must have bought the stock before 13 September 2021. Payment date: 18 October 2021. Trailing yield: 2.1%. Lower than top quartile of Taiwanese dividend payers (5.2%). In line with average of industry peers (2.3%).Reported Earnings • Aug 15Second quarter 2021 earnings released: EPS NT$2.66 (vs NT$2.88 in 2Q 2020)Second quarter 2021 results: Revenue: NT$132.6m (up 26% from 2Q 2020). Net income: NT$1.22b (down 2.8% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 5% per year whereas the company’s share price has increased by 3% per year.Reported Earnings • May 13First quarter 2021 earnings released: EPS NT$4.63 (vs NT$0.48 in 1Q 2020)First quarter 2021 results: Revenue: NT$158.4m (down 49% from 1Q 2020). Net income: NT$2.12b (up NT$1.91b from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 6% per year whereas the company’s share price has increased by 7% per year.Reported Earnings • Mar 30Full year 2020 earnings released: EPS NT$8.50 (vs NT$0.68 loss in FY 2019)Full year 2020 results: Revenue: NT$717.0m (down 50% from FY 2019). Net income: NT$3.79b (up NT$4.07b from FY 2019). Over the last 3 years on average, earnings per share has increased by 6% per year whereas the company’s share price has increased by 11% per year.お知らせ • Mar 11Center Laboratories, Inc., Annual General Meeting, May 28, 2021Center Laboratories, Inc., Annual General Meeting, May 28, 2021.Is New 90 Day High Low • Jan 20New 90-day low: NT$61.90The company is down 7.0% from its price of NT$66.50 on 23 October 2020. The Taiwanese market is up 22% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 19% over the same period.Is New 90 Day High Low • Dec 20New 90-day high: NT$72.20The company is up 2.0% from its price of NT$71.10 on 22 September 2020. The Taiwanese market is up 10.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 16% over the same period.分析記事 • Nov 20We're Not Counting On Center Laboratories (GTSM:4123) To Sustain Its Statutory ProfitabilityAs a general rule, we think profitable companies are less risky than companies that lose money. However, sometimes...Reported Earnings • Nov 14Third quarter 2020 earnings released: EPS NT$2.09Third quarter 2020 results: Revenue: NT$131.5m (down 62% from 3Q 2019). Net income: NT$947.7m (up NT$917.8m from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 20% per year, which means it is tracking significantly ahead of earnings growth.Is New 90 Day High Low • Oct 28New 90-day low: NT$65.20The company is down 8.0% from its price of NT$71.02 on 30 July 2020. The Taiwanese market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 13% over the same period.Is New 90 Day High Low • Sep 24New 90-day low: NT$68.70The company is down 2.0% from its price of NT$70.26 on 24 June 2020. The Taiwanese market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 4.0% over the same period. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Center Laboratories は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測TPEX:4123 - アナリストの将来予測と過去の財務データ ( )TWD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数6/30/20261,6571,019125283N/A3/31/20261,60310,739-87128N/A12/31/20251,5169,323-18127N/A9/30/20251,5651,777-75125N/A6/30/20251,599-6680193N/A3/31/20251,633-14172318N/A12/31/20241,618-1,104216395N/A9/30/20241,575-41534241N/A6/30/20241,524-1,667-52183N/A3/31/20241,422-2,528-1,115-913N/A12/31/20231,394-995-1,135-963N/A9/30/20231,227-903-945-854N/A6/30/20231,058-1,018-1,044-1,004N/A3/31/2023951-265-110-80N/A12/31/2022768102-198-190N/A9/30/2022650-623-411-404N/A6/30/2022566-342-349-344N/A3/31/20224941,057-444-438N/A12/31/20215001,816-366-358N/A9/30/20215513,898-273-260N/A6/30/20215945,659-274-261N/A3/31/20215675,695-263-246N/A12/31/20207173,786-342-270N/A9/30/20209242,275-488-295N/A6/30/20201,1391,357-380-219N/A3/31/20201,386138N/A-270N/A12/31/20191,438-286N/A-286N/A9/30/20193,6913,769N/A-560N/A6/30/20199,3565,321N/A-178N/A3/31/201916,1185,423N/A746N/A12/31/201821,6486,084N/A618N/A9/30/201824,9002,407N/A1,161N/A6/30/201823,950876N/A895N/A3/31/201821,475718N/A1,040N/A12/31/201719,392250N/A2,014N/A9/30/201718,016-64N/A2,828N/A6/30/201716,47790N/A2,613N/A3/31/201715,58858N/A2,045N/A12/31/201615,04019N/A1,156N/A9/30/201614,541703N/A687N/A6/30/201613,269490N/A232N/A3/31/20169,804437N/A-143N/A12/31/20156,792422N/A-138N/A9/30/20153,026135N/A-749N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 4123の予測収益成長が 貯蓄率 ( 1.3% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 4123の収益がTW市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 4123の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 4123の収益がTW市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 4123の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 4123の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/17 19:48終値2026/08/17 00:00収益2026/06/30年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Center Laboratories, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Yenya KuoCapital Securities CorporationHsiu Chi LinMasterlink Securities Investment Advisory
Reported Earnings • Aug 15Second quarter 2026 earnings released: NT$13.78 loss per share (vs NT$0.96 loss in 2Q 2025)Second quarter 2026 results: NT$13.78 loss per share (further deteriorated from NT$0.96 loss in 2Q 2025). Revenue: NT$432.1m (up 14% from 2Q 2025). Net loss: NT$10.4b (loss widened NT$9.72b from 2Q 2025). Over the last 3 years on average, earnings per share has increased by 113% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.
Upcoming Dividend • Aug 10Upcoming dividend of NT$1.75 per shareEligible shareholders must have bought the stock before 17 August 2026. Payment date: 11 September 2026. Payout ratio is a comfortable 12% but the company is not cash flow positive. Trailing yield: 4.4%. Lower than top quartile of Taiwanese dividend payers (5.1%). Higher than average of industry peers (3.1%).
Reported Earnings • May 15First quarter 2026 earnings released: EPS: NT$2.00 (vs NT$0.72 in 1Q 2025)First quarter 2026 results: EPS: NT$2.00 (up from NT$0.72 in 1Q 2025). Revenue: NT$466.0m (up 23% from 1Q 2025). Net income: NT$1.97b (up 258% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 121% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.
お知らせ • Apr 01WuXi XDC Cayman Inc. (SEHK:2268) completed the acquisition of 60% stake in BioDlink International Company Limited (SEHK:1875) from a group of shareholders.WuXi XDC Cayman Inc. (SEHK:2268) proposed to acquire 60% stake in BioDlink International Company Limited (SEHK:1875) from a group of shareholders for HKD 1.9 billion on January 14, 2026. A cash consideration valued at HKD 4 per share will be paid by WuXi XDC Cayman Inc. The Board of Directors of BioDlink International Company Limited formed a special committee for the transaction. The transaction is subject to minimum tender. The transaction is expected to close on March 27, 2026. As of March 13, 2026 The Offeror received valid acceptances for 46.54% of the company's issued share capital by the first closing date. However, the acceptance condition of holding at least 60% of voting rights was not met, leading to an extension of the offer to March 27, 2026. As of March 17, 2026, the Offeror had received valid acceptances for the Share Offer in respect of 463,672,734 Offer Shares, representing approximately 60% of the total issued share capital of BioDlink International Company Limited. the Offeror had received valid acceptances for the Option Offer in respect of 6,512,600 Share Options representing approximately 85.33% of the total outstanding Share Options. The transaction is expected to close on March 31, 2026. Citigroup Global Markets Asia Limited acted as financial advisor for WuXi XDC Cayman Inc. Grand Moore Capital Limited act as financial advisor for special committee. Tricor Investor Services Limited acted as Registrar to BioDlink International Company Limited. Grand Moore Capital Limited acted as financial advisor to independent board committee of BioDlink International Company Limited. WuXi XDC Cayman Inc. (SEHK:2268) completed the acquisition of 60% stake in BioDlink International Company Limited (SEHK:1875) from a group of shareholders on March 31, 2026.
New Risk • Mar 04New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 37% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 24% per year over the past 5 years. High level of non-cash earnings (37% accrual ratio).
Reported Earnings • Mar 04Full year 2025 earnings released: EPS: NT$12.33 (vs NT$1.48 loss in FY 2024)Full year 2025 results: EPS: NT$12.33 (up from NT$1.48 loss in FY 2024). Revenue: NT$1.52b (down 6.3% from FY 2024). Net income: NT$9.32b (up NT$10.4b from FY 2024). Over the last 3 years on average, earnings per share has increased by 97% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.
お知らせ • Mar 04Center Laboratories, Inc., Annual General Meeting, Jun 12, 2026Center Laboratories, Inc., Annual General Meeting, Jun 12, 2026. Location: 4 floor building. e no,19-11, san ch`ung rd., nangang district, taipei city Taiwan
Reported Earnings • Nov 12Third quarter 2025 earnings released: EPS: NT$3.80 (vs NT$0.36 in 3Q 2024)Third quarter 2025 results: EPS: NT$3.80 (up from NT$0.36 in 3Q 2024). Revenue: NT$359.1m (down 8.5% from 3Q 2024). Net income: NT$2.72b (up NT$2.44b from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
Upcoming Dividend • Sep 26Upcoming dividend of NT$0.76 per shareEligible shareholders must have bought the stock before 03 October 2025. Payment date: 10 November 2025. The company is not currently making a profit and there are not enough cash flows to support it either. Trailing yield: 1.9%. Lower than top quartile of Taiwanese dividend payers (5.3%). Lower than average of industry peers (2.5%).
Reported Earnings • Aug 17Second quarter 2025 earnings released: NT$1.01 loss per share (vs NT$0.10 loss in 2Q 2024)Second quarter 2025 results: NT$1.01 loss per share (further deteriorated from NT$0.10 loss in 2Q 2024). Revenue: NT$378.7m (down 8.4% from 2Q 2024). Net loss: NT$726.5m (loss widened NT$654.1m from 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.
Reported Earnings • May 14First quarter 2025 earnings released: EPS: NT$0.76 (vs NT$0.78 loss in 1Q 2024)First quarter 2025 results: EPS: NT$0.76 (up from NT$0.78 loss in 1Q 2024). Revenue: NT$378.9m (up 4.3% from 1Q 2024). Net income: NT$549.1m (up NT$1.09b from 1Q 2024). Over the last 3 years on average, earnings per share has fallen by 48% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.
お知らせ • May 03Center Laboratories, Inc. to Report Q1, 2025 Results on May 12, 2025Center Laboratories, Inc. announced that they will report Q1, 2025 results on May 12, 2025
Reported Earnings • Mar 19Full year 2024 earnings released: NT$1.55 loss per share (vs NT$1.50 loss in FY 2023)Full year 2024 results: NT$1.55 loss per share (further deteriorated from NT$1.50 loss in FY 2023). Revenue: NT$1.62b (up 16% from FY 2023). Net loss: NT$1.10b (loss widened 11% from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 78 percentage points per year, which is a significant difference in performance.
お知らせ • Mar 12+ 1 more updateCenter Laboratories, Inc., Annual General Meeting, Jun 26, 2025Center Laboratories, Inc., Annual General Meeting, Jun 26, 2025. Location: 4 floor building. e no,19-11, san ch`ung rd., nangang district, taipei city Taiwan
お知らせ • Mar 04Center Laboratories, Inc. to Report Fiscal Year 2024 Results on Mar 11, 2025Center Laboratories, Inc. announced that they will report fiscal year 2024 results on Mar 11, 2025
Reported Earnings • Nov 19Third quarter 2024 earnings released: EPS: NT$0.38 (vs NT$1.49 loss in 3Q 2023)Third quarter 2024 results: EPS: NT$0.38 (up from NT$1.49 loss in 3Q 2023). Revenue: NT$392.5m (up 15% from 3Q 2023). Net income: NT$273.3m (up NT$1.25b from 3Q 2023). Profit margin: 70% (up from net loss in 3Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 112 percentage points per year, which is a significant difference in performance.
お知らせ • Nov 05Center Laboratories, Inc. to Report Q3, 2024 Results on Nov 12, 2024Center Laboratories, Inc. announced that they will report Q3, 2024 results on Nov 12, 2024
Reported Earnings • Aug 15Second quarter 2024 earnings released: NT$0.10 loss per share (vs NT$1.43 loss in 2Q 2023)Second quarter 2024 results: NT$0.10 loss per share (improved from NT$1.43 loss in 2Q 2023). Revenue: NT$413.4m (up 32% from 2Q 2023). Net loss: NT$72.5m (loss narrowed 92% from 2Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 127 percentage points per year, which is a significant difference in performance.
お知らせ • Aug 06Center Laboratories, Inc. to Report Q2, 2024 Results on Aug 13, 2024Center Laboratories, Inc. announced that they will report Q2, 2024 results on Aug 13, 2024
Upcoming Dividend • Jul 26Upcoming dividend of NT$1.43 per shareEligible shareholders must have bought the stock before 02 August 2024. Payment date: 30 August 2024. The company is not currently making a profit and is not cash flow positive. Trailing yield: 2.8%. Lower than top quartile of Taiwanese dividend payers (4.3%). Higher than average of industry peers (2.0%).
Reported Earnings • May 20First quarter 2024 earnings released: NT$0.78 loss per share (vs NT$1.52 profit in 1Q 2023)First quarter 2024 results: NT$0.78 loss per share (down from NT$1.52 profit in 1Q 2023). Revenue: NT$363.4m (up 8.5% from 1Q 2023). Net loss: NT$541.0m (down 155% from profit in 1Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 126 percentage points per year, which is a significant difference in performance.
お知らせ • May 16Center Laboratories, Inc. Announces the Resignation of Lin Shirley Yi-Hsien as Independent DirectorCenter Laboratories, Inc. received the resignation letter from the independent director LIN SHIRLEY YI-HSIEN on May 15,2024, effective immediately. Reason for the change is personal reason.
お知らせ • May 05Center Laboratories, Inc. to Report Q1, 2024 Results on May 13, 2024Center Laboratories, Inc. announced that they will report Q1, 2024 results at 9:00 AM, Taipei Standard Time on May 13, 2024
お知らせ • Mar 29Center Laboratories, Inc., Annual General Meeting, Jun 25, 2024Center Laboratories, Inc., Annual General Meeting, Jun 25, 2024.
Reported Earnings • Mar 21Full year 2023 earnings released: NT$1.50 loss per share (vs NT$0.16 profit in FY 2022)Full year 2023 results: NT$1.50 loss per share (down from NT$0.16 profit in FY 2022). Revenue: NT$1.39b (up 82% from FY 2022). Net loss: NT$995.4m (down NT$1.10b from profit in FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 111 percentage points per year, which is a significant difference in performance.
New Risk • Nov 18New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 5.8% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Earnings have declined by 41% per year over the past 5 years. Minor Risk Shareholders have been diluted in the past year (5.8% increase in shares outstanding).
Reported Earnings • Nov 14Third quarter 2023 earnings released: NT$1.49 loss per share (vs NT$1.68 loss in 3Q 2022)Third quarter 2023 results: NT$1.49 loss per share (improved from NT$1.68 loss in 3Q 2022). Revenue: NT$341.2m (up 98% from 3Q 2022). Net loss: NT$978.7m (loss narrowed 11% from 3Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 94 percentage points per year, which is a significant difference in performance.
Upcoming Dividend • Sep 01Upcoming dividend of NT$0.99 per share at 1.9% yieldEligible shareholders must have bought the stock before 08 September 2023. Payment date: 13 October 2023. The company is not currently making a profit and is not cash flow positive. Trailing yield: 1.9%. Lower than top quartile of Taiwanese dividend payers (5.6%). Higher than average of industry peers (1.5%).
Reported Earnings • Aug 12Second quarter 2023 earnings released: NT$1.57 loss per share (vs NT$0.31 loss in 2Q 2022)Second quarter 2023 results: NT$1.57 loss per share (further deteriorated from NT$0.31 loss in 2Q 2022). Revenue: NT$312.3m (up 53% from 2Q 2022). Net loss: NT$933.0m (loss widened 419% from 2Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 79 percentage points per year, which is a significant difference in performance.
お知らせ • Aug 12Center Laboratories, Inc. Announces Cash Dividend Distribution for the Year 2022, Payable on October 13, 2023The Board of Directors of Center Laboratories, Inc. announced dividend distribution for the year 2022. Appropriations of earnings in cash dividends to shareholders (TWD per share): TWD 1.0. Total amount of cash dividends to shareholders (TWD): 594,755,996. Ex-rights (Ex-dividend) date: September 08, 2023. Ex-rights (Ex-dividend) record date: September 16, 2023. Last date before book closure: September 11, 2023. Payment date of cash dividend distribution: October 13, 2023.
Reported Earnings • Apr 01Full year 2022 earnings released: EPS: NT$0.17 (vs NT$3.14 in FY 2021)Full year 2022 results: EPS: NT$0.17 (down from NT$3.14 in FY 2021). Revenue: NT$767.7m (up 54% from FY 2021). Net income: NT$102.2m (down 94% from FY 2021). Profit margin: 13% (down from 363% in FY 2021). Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has increased by 15% per year, which means it is well ahead of earnings.
お知らせ • Dec 09Center Laboratories, Inc. Announces Executive AppointmentsCenter Laboratories, Inc. announced that Mao, An-Ni - Manager of the Finance and Accounting Department of Center Laboratories, Inc., as financial and accounting officer; and Tang, Ching-Yuh /Manager of the Post-Investment Management Department of Center Laboratories, Inc. as corporate governance officer and acting spokesperson, effective December 8, 2022.since Mrs. Wang, Su-Chi was elected as the company's new Chairperson by the extraordinary board of directors' meeting on November 30, 2022; she resigned from the positions of the company's financial and accounting officer, corporate governance officer, and acting spokesperson, effective November 30, 2022.
お知らせ • Dec 03Center Laboratories, Inc. Announces Management ChangesCenter Laboratories, Inc. announced since Mrs. Wang, Su-Chi was elected as the company's new Chairperson by the extraordinary board of directors' meeting on November 30, 2022; she resigned from the positions of the company's financial and accounting officer, corporate governance officer, and acting spokesperson, effective November 30, 2022.
Board Change • Nov 16Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 6 new directors. No experienced directors. 1 highly experienced director. 2 independent directors (5 non-independent directors). Chairman of the Board Rong-Jin Lin is the most experienced director on the board, commencing their role in 2013. Independent Director Shirley Lin was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Upcoming Dividend • Sep 01Upcoming dividend of NT$2.43 per shareEligible shareholders must have bought the stock before 08 September 2022. Payment date: 14 October 2022. The company is not currently making a profit and is not cash flow positive. Trailing yield: 3.9%. Lower than top quartile of Taiwanese dividend payers (6.4%). Higher than average of industry peers (2.4%).
Reported Earnings • Aug 14Second quarter 2022 earnings released: NT$0.36 loss per share (vs NT$2.42 profit in 2Q 2021)Second quarter 2022 results: NT$0.36 loss per share (down from NT$2.42 profit in 2Q 2021). Revenue: NT$204.6m (up 54% from 2Q 2021). Net loss: NT$179.9m (down 115% from profit in 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings.
お知らせ • Aug 12Center Laboratories, Inc. Announces Cash Dividend Distribution for the Year 2021The Board of Directors of Center Laboratories, Inc. announced dividend distribution for the year 2021. Appropriations of earnings in cash dividends to shareholders (TWD per share): TWD 2.5. Total amount of cash dividends to shareholders (TWD): 1,262,621,868. Ex-rights (Ex-dividend) date: September 08, 2022. Ex-rights (Ex-dividend) record date: September 17, 2022. Last date before book closure: September 12, 2022. Payment date of cash dividend distribution: October 14, 2022.
お知らせ • May 21Center Laboratories, Inc. Elects DirectorsCenter Laboratories, Inc. elected Lin, Jung Chin, Tsai, Chang-Hai and LIN SHIRLEY YI-HSIEN as directors, at its 2022 Annual Shareholders' Meeting held on May 20, 2022.
Reported Earnings • May 14First quarter 2022 earnings released: EPS: NT$2.69 (vs NT$4.21 in 1Q 2021)First quarter 2022 results: EPS: NT$2.69 (down from NT$4.21 in 1Q 2021). Revenue: NT$152.0m (down 4.0% from 1Q 2021). Net income: NT$1.36b (down 36% from 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings.
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 7 non-independent directors. Independent Director Mei-Yueh Ho was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Mar 31Full year 2021 earnings released: EPS: NT$3.60 (vs NT$7.73 in FY 2020)Full year 2021 results: EPS: NT$3.60 (down from NT$7.73 in FY 2020). Revenue: NT$500.1m (down 30% from FY 2020). Net income: NT$1.82b (down 52% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.
お知らせ • Mar 04Center Laboratories, Inc., Annual General Meeting, May 20, 2022Center Laboratories, Inc., Annual General Meeting, May 20, 2022. Location: Building E, Room 447, 4F, No. 19-11, Sanchong Road, Nangang District,Taipei City, Taiwan (Nankang Software Incubator) Taipei City Taiwan Agenda: To discuss 2021 business report; to discuss audit committee review report ; to consider Amendment to the ” Articles of Incorporation; to release non-competition restrictions on newly elected directors of the company and other subject matters.
Reported Earnings • Nov 12Third quarter 2021 earnings released: NT$1.61 loss per share (vs NT$1.90 profit in 3Q 2020)The company reported a poor third quarter result with weaker earnings, revenues and control over costs. Third quarter 2021 results: Revenue: NT$87.9m (down 33% from 3Q 2020). Net loss: NT$813.4m (down 186% from profit in 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.
Upcoming Dividend • Sep 06Upcoming dividend of NT$1.50 per shareEligible shareholders must have bought the stock before 13 September 2021. Payment date: 18 October 2021. Trailing yield: 2.1%. Lower than top quartile of Taiwanese dividend payers (5.2%). In line with average of industry peers (2.3%).
Reported Earnings • Aug 15Second quarter 2021 earnings released: EPS NT$2.66 (vs NT$2.88 in 2Q 2020)Second quarter 2021 results: Revenue: NT$132.6m (up 26% from 2Q 2020). Net income: NT$1.22b (down 2.8% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 5% per year whereas the company’s share price has increased by 3% per year.
Reported Earnings • May 13First quarter 2021 earnings released: EPS NT$4.63 (vs NT$0.48 in 1Q 2020)First quarter 2021 results: Revenue: NT$158.4m (down 49% from 1Q 2020). Net income: NT$2.12b (up NT$1.91b from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 6% per year whereas the company’s share price has increased by 7% per year.
Reported Earnings • Mar 30Full year 2020 earnings released: EPS NT$8.50 (vs NT$0.68 loss in FY 2019)Full year 2020 results: Revenue: NT$717.0m (down 50% from FY 2019). Net income: NT$3.79b (up NT$4.07b from FY 2019). Over the last 3 years on average, earnings per share has increased by 6% per year whereas the company’s share price has increased by 11% per year.
お知らせ • Mar 11Center Laboratories, Inc., Annual General Meeting, May 28, 2021Center Laboratories, Inc., Annual General Meeting, May 28, 2021.
Is New 90 Day High Low • Jan 20New 90-day low: NT$61.90The company is down 7.0% from its price of NT$66.50 on 23 October 2020. The Taiwanese market is up 22% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 19% over the same period.
Is New 90 Day High Low • Dec 20New 90-day high: NT$72.20The company is up 2.0% from its price of NT$71.10 on 22 September 2020. The Taiwanese market is up 10.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 16% over the same period.
分析記事 • Nov 20We're Not Counting On Center Laboratories (GTSM:4123) To Sustain Its Statutory ProfitabilityAs a general rule, we think profitable companies are less risky than companies that lose money. However, sometimes...
Reported Earnings • Nov 14Third quarter 2020 earnings released: EPS NT$2.09Third quarter 2020 results: Revenue: NT$131.5m (down 62% from 3Q 2019). Net income: NT$947.7m (up NT$917.8m from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 20% per year, which means it is tracking significantly ahead of earnings growth.
Is New 90 Day High Low • Oct 28New 90-day low: NT$65.20The company is down 8.0% from its price of NT$71.02 on 30 July 2020. The Taiwanese market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 13% over the same period.
Is New 90 Day High Low • Sep 24New 90-day low: NT$68.70The company is down 2.0% from its price of NT$70.26 on 24 June 2020. The Taiwanese market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 4.0% over the same period.